Dissecting the psoriasis transcriptome: Inflammatory- and cytokine-driven gene expression in lesions from 163 patients

BMC Genomics

Volumn 14, Issue 1, 2013, Pages

  Swindell, William R ^a   Johnston, Andrew ^a   Voorhees, John J ^a   Elder, James T ^a   Gudjonsson, Johann E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

AP 1; Etanercept; IL 17; IL 20; Inflammation; Keratinocyte; Microarray; T cell; TNF; Transcription factor

Indexed keywords

ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 20; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTOME;

ADIPOSE TISSUE; ARTICLE; BINDING SITE; CELL ACTIVITY; CONTROLLED STUDY; DENDRITIC CELL; DERMIS; DIFFERENTIALLY EXPRESSED GENE; DRUG RESPONSE; EPIDERMIS; GENE; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; MONOCYTE; PSORIASIS;

BINDING SITES; CYTOKINES; DERMIS; EPIDERMIS; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; KERATINOCYTES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGAN SPECIFICITY; PROTEASOME ENDOPEPTIDASE COMPLEX; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN; SUBCUTANEOUS FAT; T-LYMPHOCYTES; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880891082     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-14-527     Document Type: Article

References (79)

1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project Global epidemiology of psoriasis: a systematic review of incidence and prevalence. in press, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project.
2. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009, 361:496-509. 10.1056/NEJMra0804595, 19641206.
3. Elder JT, Bruce AT, Gudjonsson JE, Johnston A, Stuart PE, Tejasvi T, Voorhees JJ, Abecasis GR, Nair RP. Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol 2010, 130:1213-26. 10.1038/jid.2009.319, 19812592.
4. Gudjonsson JE, Ding J, Li X, Nair RP, Tejasvi T, Qin ZS, Ghosh D, Aphale A, Gumucio DL, Voorhees JJ, Abecasis GR, Elder JT. Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol 2009, 129:2795-804. 10.1038/jid.2009.173, 2783967, 19571819.
5. Gudjonsson JE, Ding J, Johnston A, Tejasvi T, Guzman AM, Nair RP, Voorhees JJ, Abecasis GR, Elder JT. Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol 2010, 130:1829-40. 10.1038/jid.2010.36, 3128718, 20220767.
6. Swindell WR, Xing X, Stuart PE, Chen CS, Aphale A, Nair RP, Voorhees JJ, Elder JT, Johnston A, Gudjonsson JE. Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis. PLoS One 2012, 7:e34594. 10.1371/journal.pone.0034594, 3315545, 22479649.
7. Ainali C, Valeyev N, Perera G, Williams A, Gudjonsson JE, Ouzounis CA, Nestle FO, Tsoka S. Transcriptome classification reveals molecular subtypes in psoriasis. BMC Genomics 2012, 13:472. 10.1186/1471-2164-13-472, 3481433, 22971201.
8. Suárez-Fariñas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 2012, 132:2552-64. 10.1038/jid.2012.184, 3472561, 22763790.
9. Kulski JK, Kenworthy W, Bellgard M, Taplin R, Okamoto K, Oka A, Mabuchi T, Ozawa A, Tamiya G, Inoko H. Gene expression profiling of Japanese psoriatic skin reveals an increased activity in molecular stress and immune response signals. J Mol Med (Berl) 2005, 83:964-75.
10. Reischl J, Schwenke S, Beekman JM, Mrowietz U, Stürzebecher S, Heubach JF. Increased expression of Wnt5a in psoriatic plaques. J Invest Dermatol 2007, 127:163-9. 10.1038/sj.jid.5700488, 16858420.
11. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrodi SJ, Prahalad S, Guthery SL, Fischer J, Liao W, Kwok PY, Menter A, Lathrop GM, Wise CA, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM, Abecasis GR, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009, 41:199-204. 10.1038/ng.311, 2745122, 19169254.
12. Haider AS, Lowes MA, Suàrez-Fariñas M, Zaba LC, Cardinale I, Blumenberg M, Krueger JG. Cellular genomic maps help dissect pathology in human skin disease. J Invest Dermatol 2008, 128:606-15. 10.1038/sj.jid.5701067, 17928892.
13. Mitsui H, Suárez-Fariñas M, Belkin DA, Levenkova N, Fuentes-Duculan J, Coats I, Fujita H, Krueger JG. Combined use of laser capture microdissection and cDNA microarray analysis identifies locally expressed disease-related genes in focal regions of psoriasis vulgaris skin lesions. J Invest Dermatol 2012, 132:1615-26. 10.1038/jid.2012.33, 3352975, 22402443.
14. Swindell WR, Johnston A, Gudjonsson JE. Transcriptional profiles of leukocyte populations provide a tool for interpreting gene expression patterns associated with high fat diet in mice. PLoS One 2010, 5:e11861. 10.1371/journal.pone.0011861, 2912331, 20686622.
15. Swindell WR, Johnston A, Sun L, Xing X, Fisher GJ, Bulyk ML, Elder JT, Gudjonsson JE. Meta-profiles of gene expression during aging: limited similarities between mouse and human and an unexpectedly decreased inflammatory signature. PLoS One 2012, 7:e33204. 10.1371/journal.pone.0033204, 3296693, 22413003.
16. Mee JB, Johnson CM, Morar N, Burslem F, Groves RW. The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis. Am J Pathol 2007, 171:32-42. 10.2353/ajpath.2007.061067, 1941577, 17591951.
17. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M, Nograles KE, Tian S, Cardinale I, Chimenti S, Krueger JG. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011, 131:677-87. 10.1038/jid.2010.340, 21085185.
18. Bernard FX, Morel F, Camus M, Pedretti N, Barrault C, Garnier J, Lecron JC. Keratinocytes under fire of proinflammatory cytokines: bona fide innate immune cells involved in the physiopathology of chronic atopic dermatitis and psoriasis. J Allergy (Cairo) in press.
19. Yao Y, Richman L, Morehouse C, De Los Reyes M, Higgs BW, Boutrin A, White B, Coyle A, Krueger J, Kiener PA, Jallal B. Type I interferon: potential therapeutic target for psoriasis?. PLoS One 2008, 3:e2737. 10.1371/journal.pone.0002737, 2481274, 18648529.
20. Kim IH, West CE, Kwatra SG, Feldman SR, O'Neill JL. Comparative efficacy of biologics in psoriasis: a review. Am J Clin Dermatol 2012, 13:365-74. 10.2165/11633110-000000000-00000, 22967166.
21. Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, Lowes MA, Krueger JG. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009, 124:1022-10. 10.1016/j.jaci.2009.08.046, 2852188, 19895991.
22. Coimbra S, Figueiredo A, Castro E, Rocha-Pereira P, Santos-Silva A. The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol 2012, 51:389-95. 10.1111/j.1365-4632.2011.05154.x, 22435425.
23. Wang M, Master SR, Chodosh LA. Computational expression deconvolution in a complex mammalian organ. BMC Bioinformatics 2006, 7:328. 10.1186/1471-2105-7-328, 1559723, 16817968.
24. Lähdesmäki H, Shmulevich L, Dunmire V, Yli-Harja O, Zhang W. In silico microdissection of microarray data from heterogeneous cell populations. BMC Bioinformatics 2005, 6:54. 10.1186/1471-2105-6-54, 1274251, 15766384.
25. Abbas AR, Wolslegel K, Seshasayee D, Modrusan Z, Clark HF. Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. PLoS One 2009, 4:e6098. 10.1371/journal.pone.0006098, 2699551, 19568420.
26. Murakami M, Arai S, Nagai Y, Yamazaki K, Iizuka S. Subcutaneous fat distribution of the abdomen and buttocks in Japanese women aged 20 to 58 years. Appl Human Sci 1997, 16:167-77. 10.2114/jpa.16.167, 9343866.
27. Murakami M, Hikima R, Arai S, Yamazaki K, Iizuka S, Tochihara Y. Short-term longitudinal changes in subcutaneous fat distribution and body size among Japanese women in the third decade of life. Appl Human Sci 1999, 18:141-9. 10.2114/jpa.18.141, 10510517.
28. Lee Y, Hwang K. Skin thickness of Korean adults. Surg Radiol Anat 2002, 24:183-9. 10.1007/s00276-002-0034-5, 12375070.
29. Zhang YB, Tang Y, Quan XM, Qiu L, Tian XF, Liu Y, Gan LQ. Preliminary study of the ultrasonic measurement of thickness of skin in children. Zhonghua Shao Shang Za Zhi 2007, 23:352-5.
30. Tsambaos D, Mahrle G. The phospholipid pattern in the involved and the uninvolved psoriatic epidermis. Arch Dermatol Res 1979, 266:177-80. 10.1007/BF00694626, 526045.
31. Tsambaos D. Phospholipid composition of psoriatic epidermis. Br J Dermatol 1979, 100:613. 10.1111/j.1365-2133.1979.tb05590.x, 444433.
32. Vignale RA, Lasalvia E. Cutaneous lipids and psoriasis. Med Cutan Ibero Lat Am 1983, 11:7-10.
33. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE, Alefacept Clinical Study Group An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003, 139:719-727. 10.1001/archderm.139.6.719, 12810502, Alefacept Clinical Study Group.
34. Cai Y, Shen X, Ding C, Qi C, Li K, Li X, Jala VR, Zhang HG, Wang T, Zheng J, Yan J. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity 2011, 35:596-610. 10.1016/j.immuni.2011.08.001, 3205267, 21982596.
35. Seung NR, Park EJ, Kim CW, Kim KH, Kim KJ, Cho HJ, Park HR. Comparison of expression of heat-shock protein 60, toll-like receptors 2 and 4, and T-cell receptor gammadelta in plaque and guttate psoriasis. J Cutan Pathol 2007, 34:903-11. 10.1111/j.1600-0560.2007.00756.x, 18001412.
36. Laggner U, Di Meglio P, Perera GK, Hundhausen C, Lacy KE, Ali N, Smith CH, Hayday AC, Nickoloff BJ, Nestle FO. Identification of a novel proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role in psoriasis. J Immunol 2011, 187:2783-93. 10.4049/jimmunol.1100804, 3187621, 21813772.
37. Bovenschen HJ, Seyger MM, Van de Kerkhof PC. Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation. Br J Dermatol 2005, 153:72-78. 10.1111/j.1365-2133.2005.06538.x, 16029329.
38. Di Meglio P, Perera GK, Nestle FO. The multitasking organ: recent insights into skin immune function. Immunity 2011, 35:857-69. 10.1016/j.immuni.2011.12.003, 22195743.
39. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31:331-41. 10.1016/j.immuni.2009.08.001, 19682929.
40. Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009, 31:321-30. 10.1016/j.immuni.2009.06.020, 19682928.
41. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group, Durez P, Tak PP, Gomez-Reino JJ; Rheumatoid Arthritis Study Group, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD; Uveitis Study Group, Rose K, Haider A, Di Padova F Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010, 2:52ra72. 10.1126/scitranslmed.3001107, 20926833, Psoriasis Study Group, Durez P, Tak PP, Gomez-Reino JJ; Rheumatoid Arthritis Study Group, Foster CS, Kim RY, Samson CM, Falk NS, Chu DS, Callanan D, Nguyen QD; Uveitis Study Group, Rose K, Haider A, Di Padova F.
42. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE, EXPRESS study investigators Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005, 366:1367-74. 10.1016/S0140-6736(05)67566-6, 16226614, EXPRESS study investigators.
43. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008, 58:106-15. 10.1016/j.jaad.2007.09.010, 17936411.
44. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, PHOENIX 1 study investigators Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-74. 10.1016/S0140-6736(08)60725-4, 18486739, PHOENIX 1 study investigators.
45. Logsdon NJ, Deshpande A, Harris BD, Rajashankar KR, Walter MR. Structural basis for receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cytokines. Proc Natl Acad Sci U S A 2012, 109:12704-9. 10.1073/pnas.1117551109, 3412030, 22802649.
46. Tohyama M, Hanakawa Y, Shirakata Y, Dai X, Yang L, Hirakawa S, Tokumaru S, Okazaki H, Sayama K, Hashimoto K. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol 2009, 39:2779-88. 10.1002/eji.200939473, 19731362.
47. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, Carollo S, Eagan M, Foster D, Haldeman BA, Hammond A, Haugen H, Jelinek L, Kelly JD, Madden K, Maurer MF, Parrish-Novak J, Prunkard D, Sexson S, Sprecher C, Waggie K, West J, Whitmore TE, Yao L, Kuechle MK, Dale BA, Chandrasekher YA. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 2001, 104:9-19. 10.1016/S0092-8674(01)00187-8, 11163236.
48. He M, Liang P. IL-24 transgenic mice: in vivo evidence of overlapping functions for IL-20, IL-22, and IL-24 in the epidermis. J Immunol 2010, 184:1793-8. 10.4049/jimmunol.0901829, 20061404.
49. Nickoloff BJ, Xin H, Nestle FO, Qin JZ. The cytokine and chemokine network in psoriasis. Clin Dermatol 2007, 25:568-73. 10.1016/j.clindermatol.2007.08.011, 18021894.
50. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366:1190-9. 10.1056/NEJMoa1109997, 22455413.
51. Viguier M, Guigue P, Pagès C, Smahi A, Bachelez H. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Intern Med 2010, 153:66-7. 10.7326/0003-4819-153-1-201007060-00030, 20621920.
52. Kunz S, Wolk K, Witte E, Witte K, Doecke WD, Volk HD, Sterry W, Asadullah K, Sabat R. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 2006, 15:991-1004. 10.1111/j.1600-0625.2006.00516.x, 17083366.
53. Otkjaer K, Kragballe K, Johansen C, Funding AT, Just H, Jensen UB, Sørensen LG, Nørby PL, Clausen JT, Iversen L. IL-20 gene expression is induced by IL-1beta through mitogen-activated protein kinase and NF-kappaB-dependent mechanisms. J Invest Dermatol 2007, 127:1326-36. 10.1038/sj.jid.5700713, 17255956.
54. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007, 8:942-9.
55. Elder JT, Tavakkol A, Klein SB, Zeigler ME, Wicha M, Voorhees JJ. Protooncogene expression in normal and psoriatic skin. J Invest Dermatol 1990, 94:19-25. 10.1111/1523-1747.ep12873313, 1688596.
56. Sobolev VV, Zolotorenko AD, Soboleva AG, Elkin AM, Il'ina SA, Serov DN, Potekaev NN, Tkachenko SB, Minnibaev MT, Piruzyan AL. Effects of expression of transcriptional factor AP-1 FOSL1 gene on psoriatic process. Bull Exp Biol Med 2011, 150:632-4. 10.1007/s10517-011-1208-0, 22235402.
57. Johansen C, Kragballe K, Rasmussen M, Dam TN, Iversen L. Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin. Br J Dermatol 2004, 151:600-7. 10.1111/j.1365-2133.2004.06088.x, 15377346.
58. Mehic D, Bakiri L, Ghannadan M, Wagner EF, Tschachler E. Fos and jun proteins are specifically expressed during differentiation of human keratinocytes. J Invest Dermatol 2005, 124:212-20. 10.1111/j.0022-202X.2004.23558.x, 15654976.
59. Han B, Rorke EA, Adhikary G, Chew YC, Xu W, Eckert RL. Suppression of AP1 transcription factor function in keratinocyte suppresses differentiation. PLoS One 2012, 7:e36941. 10.1371/journal.pone.0036941, 3359321, 22649503.
60. Rorke EA, Adhikary G, Jans R, Crish JF, Eckert RL. AP1 factor inactivation in the suprabasal epidermis causes increased epidermal hyperproliferation and hyperkeratosis but reduced carcinogen-dependent tumor formation. Oncogene 2010, 29:5873-82. 10.1038/onc.2010.315, 2974027, 20818430.
61. Efimova T, LaCelle P, Welter JF, Eckert RL. Regulation of human involucrin promoter activity by a protein kinase C, Ras, MEKK1, MEK3, p38/RK, AP1 signal transduction pathway. J Biol Chem 1998, 273:24387-95. 10.1074/jbc.273.38.24387, 9733728.
62. Gudjonsson JE, Johnston A, Dyson M, Valdimarsson H, Elder JT. Mouse models of psoriasis. J Invest Dermatol 2007, 127:1292-308. 10.1038/sj.jid.5700807, 17429444.
63. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, Scheuch H, Angel P, Tschachler E, Wagner EF. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005, 437:369-75. 10.1038/nature03963, 16163348.
64. Tejasvi T, Stuart PE, Chandran V, Voorhees JJ, Gladman DD, Rahman P, Elder JT, Nair RP. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 2012, 132:593-600. 10.1038/jid.2011.376, 3278539, 22113471.
65. Vasilopoulos Y, Manolika M, Zafiriou E, Sarafidou T, Bagiatis V, Krüger-Krasagaki S, Tosca A, Patsatsi A, Sotiriadis D, Mamuris Z, Roussaki-Schulze A. Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther 2012, 16:29-34. 10.1007/BF03256427, 22111980.
66. Bolstad BM, Collin F, Brettschneider J, Simpson K, Cope L, Irizarry RA, Speed TP. Quality assessment of affymetrix GeneChip data. Bioinformatics and Computational Biology Solutions using R and Bioconductor 2005, 33-47. New York: Springer, Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S.
67. Heber S, Sick B. Quality assessment of affymetrix GeneChip data. OMICS 2006, 10:358-68. 10.1089/omi.2006.10.358, 17069513.
68. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of affymetrix GeneChip probe level data. Nucleic Acids Res 2003, 31:e15. 10.1093/nar/gng015, 150247, 12582260.
69. Stalteri MA, Harrison AP. Interpretation of multiple probe sets mapping to the same gene in Affymetrix GeneChips. BMC Bioinformatics 2007, 8:13. 10.1186/1471-2105-8-13, 1784106, 17224057.
70. Liu WM, Mei R, Di X, Ryder TB, Hubbell E, Dee S, Webster TA, Harrington CA, Ho MH, Baid J, Smeekens SP. Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics 2002, 18:1593-9. 10.1093/bioinformatics/18.12.1593, 12490443.
71. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:3.
72. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a powerful and practical approach to multiple testing. J Roy Stat Soc B 1995, 57:289-300.
73. Philippakis AA, Busser BW, Gisselbrecht SS, He FS, Estrada B, Michelson AM, Bulyk ML. Expression-guided in silico evaluation of candidate cis regulatory codes for Drosophila muscle founder cells. PLoS Comput Biol 2006, 2:e53. 10.1371/journal.pcbi.0020053, 1464814, 16733548.
74. Portales-Casamar E, Thongjuea S, Kwon AT, Arenillas D, Zhao X, Valen E, Yusuf D, Lenhard B, Wasserman WW, Sandelin A. JASPAR 2010: the greatly expanded open-access database of transcription factor binding profiles. Nucleic Acids Res 2010, 38:D105-10. 10.1093/nar/gkp950, 2808906, 19906716.
75. Robasky K, Bulyk ML. UniPROBE, update 2011: expanded content and search tools in the online database of protein-binding microarray data on protein-DNA interactions. Nucleic Acids Res 2011, 39:D124-8. 10.1093/nar/gkq992, 3013812, 21037262.
76. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A, Reuter I, Chekmenev D, Krull M, Hornischer K, Voss N, Stegmaier P, Lewicki-Potapov B, Saxel H, Kel AE, Wingender E. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 2006, 34:D108-10. 10.1093/nar/gkj143, 1347505, 16381825.
77. Swindell WR, Johnston A, Xing X, Little A, Robichaud P, Voorhees JJ, Fisher G, Gudjonsson JE. Robust shifts in S100a9 expression with aging: a novel mechanism for chronic inflammation. Sci Rep 2013, 3:1215. 3564041, 23386971.
78. Wasserman WW, Sandelin A. Applied bioinformatics for the identification of regulatory elements. Nat Rev Genet 2004, 5:276-87. 10.1038/nrg1315, 15131651.
79. Hastie T, Tibshirani R. Generalized Additive Models 1990, London: Chapman and Hall.